Tilray's Stock Reaction to U.S. Marijuana Rescheduling Policy
Tilray (TLRY) initially surged on news of U.S. marijuana rescheduling but later lost momentum as investors realized the policy change applied only to FDA-approved and state-licensed medical cannabis, not the broader adult-use market. The limited scope of the policy shift led to a reversal in the stock's gains, highlighting the sensitivity of the cannabis sector to policy details.
Tickers: $TLRY
Topics: cannabis policy federal regulation stock market reaction Tilray